| Cassava Sciences is a clinical-stage biotechnology company. Co. focuses on detecting and treating neurodegenerative diseases, such as Alzheimer's disease. Co.'s science is based on stabilizing, but not removing a protein in the brain. Co.'s primary product candidate, simufilam, is a proprietary small molecule (oral) drug. Simufilam targets an altered form of a protein called filamin A in the Alzheimer's brain. Co. is conducting a Phase 3 program with simufilam in patients with mild-to-moderate Alzheimer's disease dementia. Co.'s investigational product candidate, called SavaDx, is an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The SAVA YTD return is shown above.
The YTD Return on the SAVA YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether SAVA YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SAVA YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.